JPRN-UMIN000003583招募中1 期
Phase I trial of S-1 with Lapatinb for metastatic breast cancer - Phase I trial of S-1 with Lapatinb for metastatic breast cancer
St. Luke's International Hospital0 个研究点目标入组 18 人开始时间: 2010年5月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1.with severe allergy to S-1 or Lapatinib 2.with active double cancer 3.infection,diarrhea,paralysis of intestine and intestinal obstruction which are judged to interfere with treatment,diabetes with incontrollable,and other sever complications 4.with mental disorder which become problem on clinical practice 5.with heart disease which become problem on clinical practice 6.with interstitial pneumonitis or with history of interstitial pneumonitis 7.with heart failure or with history of heart failure 8.with sever bone-marrow suppression, renal disorder,liver disorder 9.with large pleural effusion, or accumulation of ascitic fluid 10.with water diarrhea at the registration 11.treatment with flucytosine 12.pregnant,women who like be pregnant 13.doctor's decision not to be registered to this study
研究者
相似试验
已完成
1 期
Phase I trial of S-1 plus Lapatinib in patients with HER-2 positive metastatic breast cancerbreast cancerJPRN-UMIN000004921Tokai University School of Medicine6
尚未招募
Unknown
The first line Lazertinib treatment for metastatic EGFRm NSCLC; the real world evidence in South KoreaNeoplasmsKCT0009698Hallym University Medical Center500
进行中（未招募）
1 期
A Phase II Study of Lapatinib for Brain Metastases in Subjectswith ErbB2-Positive Breast Cancer Following Trastuzumab basedSystemic Therapy and Cranial RadiotherapyProgressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.EUCTR2005-003944-68-GRGlaxoSmithKline R&D Ltd220
进行中（未招募）
1 期
A Phase II Study of Lapatinib for Brain Metastases in Subjectswith ErbB2-Positive Breast Cancer Following Trastuzumab basedSystemic Therapy and Cranial RadiotherapyProgressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.EUCTR2005-003944-68-BEGlaxoSmithKline R&D Ltd220
进行中（未招募）
1 期
A Study of Lapatinib for Brain Metastases in Subjects with ErbB2-PositiveBreast Cancer Following Trastuzumab Therapy and Cranial RadiotherapyEUCTR2005-003944-68-GBovartis Pharma Services AG220